AI assistant
Sending…
Cardiff Oncology, Inc. — Director's Dealing 2021
Jun 14, 2021
33967_dirs_2021-06-14_3170c808-7af9-458f-8c3a-1806fdbba5c7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-06-10
Reporting Person: Kelemen Vicki (Exec. VP and COO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-10 | Stock Options | $7.98 | A | 200928 | Acquired | 2031-06-10 | Common Stock (200928.0) | Direct |
Footnotes
F1: 50,232 vest on 6/10/2022. 4,186 vest monthly for 36 months beginning on 7/10/2022 through 6/10/2025.
More from Cardiff Oncology, Inc.
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Regulatory Filings
2026
May 14
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
Apr 9
Regulatory Filings
2026
Feb 25
Regulatory Filings
2026
Feb 24
Annual Report
2026
Feb 24
Director's Dealing
2026
Feb 18
Director's Dealing
2026
Feb 18